



Claims:

1. A compound of formula I




wherein R_1 and R_2 , independently, are hydrogen, (C_{1-4}) alkyl, halogen, hydroxy, (C_{1-4}) alkoxy, di (C_{1-4}) alkylamino, (C_{1-4}) alkylthio, cyano or trifluoromethyl, R_3 is hydrogen or (C_{1-4}) alkyl and n is 1 or 2, in free base or acid addition salt form.

2. A process for the preparation of a compound of formula I as defined in claim 1, or a salt thereof, which comprises the step of reacting a compound of formula II



wherein R_1 and R_2 are as defined in claim 1, with a compound of formula III



wherein R_3 and n are as defined in claim 1, and recovering the resulting compound of formula I in free base or acid addition salt form.

3. A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.
4. A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use in the treatment of psychotic and neurodegenerative disorders.
5. A pharmaceutical composition comprising a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.
6. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the treatment of psychotic and neurodegenerative disorders.
7. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment of psychotic and neurodegenerative disorders.
8. A method for the treatment of psychotic and neurodegenerative disorders, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form.